Citations

Clear

633 citation(s) found for "Reid, J".

Improving Hyperglycemia Management in the Intensive Care Unit
Osburne, Robert C., Stockton, Lawrence, Baird, Marianne , Harmon, Valerie L., Keddo, Annie, Pounds, Teresa, Lowey, Linda, Reid, Joyce, McGowan, Kathryn A., Davidson, Paul C., Cook, Curtiss B.

Mayo Clinic

The Diabetes Educator | June 13, 2006 | Volume: 32 | Issue: 3 | Pages: 394-403

10.1177/0145721706288072 | PMID 16772655 Get It

Purpose The purpose of this study was to assess the feasibility of a nurse-driven effort to improve hyperglycemia management in the intensive care unit (ICU) setting. Methods The setting was the ICU of a large urban hospital. The program was composed of 3 components: nurses as leaders, a clinical pathway to identify patients in need of hyperglycemia therapy, and implementation of a redesigned insulin infusion algorithm (the Columnar Insulin Dosing Chart). Time to reach a target glucose range of 80 to 110 mg/dL (4.4-6.1 mmol/L) was evaluated. Results One hundred sixteen ICU nurses were trained in the project. The Columnar Insulin Dosing Chart was applied to 20 patients. The average time required to reach the target blood glucose range was 12.8 hours. Below-target blood glucose levels were 6.9% of all blood glucose levels recorded, but only 0.9% were below 60 mg/dL (3.3 mmol/L). There was no sustained hypoglycemia, and no persistent clinical findings attributable to hypoglycemia were noted. Barriers to implementing the project included an increased nursing workload, the need for more finger-stick blood glucose monitors, and the need to acquire new finger-lancing devices that allowed for shallower skin puncture and increased patient comfort. Conclusions Tighter glycemic control goals can be attained in a busy ICU by a nurse-led team using a pathway for identifying and treating hyperglycemia, clear decision support tools, and adequate nurse education. The novel chart based insulin infusion algorithm chosen as the standard for this pilot was an effective tool for reducing the blood glucose to target range with no clinically significant hypoglycemia.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward
Kelloff, Gary J. , Lippman, Scott M. , Dannenberg, Andrew J. , Sigman, Caroline C. , Pearce, Homer L., Reid, Brian J. , Szabó, Éva , Jordan, V. Craig , Spitz, Margaret R., Papadimitrakopoulou, Vali A., Lotan, Reuben, Aggarwal, Bharat B. , Bresalier, Robert S. , Kim, Jeri , Lu, Karen H. , Thomas, Melanie E., Rhodes, Helen, Brewer, Molly, Follen, Michele , Shin, Dong M. , Parnes, Howard L. , Siegfried, Jill M. , Evans, Alison A., Blot, William J. , Chow, Wong‐Ho , Blount, Patricia L., Wang, Kenneth K. , Lam, Stephen , Lee, J. Jack, Dubinett, Steven M., Engstrom, Paul F., Meyskens, Frank L. , O’Shaughnessy, Joyce , Hawk, Ernest T. , Levin, Bernard, Nelson, William G. , Hong, Waun Ki , Prevention, for the AACR Task Force on Cancer, Lee, J. Jack , Mills, Gordon B. , Arun, Banu , Maley, Carlo C. , Lee, J. Jack, Prevention, for the AACR Task Force on Cancer, Szabo, Eva , Lee, J Jack

Mayo Clinic

Clinical Cancer Research | June 8, 2006 | Volume: 12 | Issue: 12 | Pages: 3661-3697

10.1158/1078-0432.ccr-06-1104 | PMID 16778094 Get It

AbstractThis article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.
A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMA
Halling, Kevin C. , King, Walter, Соколова, И. А., Meyer, Reid G., BURKHARDT, HALEH M., Halling, Amy C., Cheville, John C. , Sebo, Thomas J., Ramakumar, Sanjay, STEWART, CHRISTOPHER S., Pankratz, Shane, O’Kane, Dennis J., Seelig, Steven, Lieber, Michael M., Jenkins, Robert B.

Mayo Clinic

Journal of Urology | January 17, 2006 | Volume: 164 | Issue: 5 | Pages: 1768-1775

10.1016/s0022-5347(05)67104-2 Get It

Phase I Clinical and Pharmacokinetic Study of Flavopiridol in Children With Refractory Solid Tumors: A Children's Oncology Group Study
Whitlock, James A. , Krailo, Mark , Ruben, Stacie, Ames, Matthew M. , Owen, William F. , Reaman, Gregory H. , Reid, Joel M.

Mayo Clinic

Journal of Clinical Oncology | December 17, 2005 | Volume: 23 | Issue: 36 | Pages: 9179-9186

10.1200/jco.2004.01.0660 | PMID 16361620 Get It

Purpose To determine the dose-limiting toxicities, maximum-tolerated dose, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol (NSC 649890) when administered as a 1-hour infusion over 3 consecutive days to children with recurrent or refractory solid tumors. Patients and Methods Flavopiridol was administered as a 1-hour intravenous infusion daily for 3 consecutive days every 21 days, or when hematologic toxicity or any grade 2 or greater nonhematologic toxicity resolved. The starting dose was 37.5 mg/m2/d. Dose escalation was in cohorts of three patients in a standard fashion until dose-limiting toxicity and the maximum-tolerated dose were determined. Flavopiridol levels were measured on days 1, 2, and 3. Results Twenty-five children received flavopiridol at doses of 37.5 to 80 mg/m2/day over 3 consecutive days. The maximum-tolerated dose was 62.5 mg/m2/d. The primary dose-limiting toxicities were neutropenia and diarrhea. No antitumor effect was observed in this population. Mean peak plasma concentrations of 3.71 and 9.11 μmol/L were achieved at the end of the 1-hour infusion, following dose escalation from 37.5 mg/m2 to 80 mg/m2, respectively. The median flavopiridol plasma clearance was 8.0 L/h/m2 (range, 2.6 to 17.1 L/h/m2). Conclusion The maximum-tolerated dose of flavopiridol in children, and the recommended phase II dose for pediatric studies, was 62.5 mg/m2/day when administered as a 1-hour infusion for 3 consecutive days. Dose-limiting toxicities of neutropenia and diarrhea were similar to those in adult studies.
The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes
Walker, Denise L., Miller, Jennifer, Benson, Linda M., Tomlinson, Andrew J., Naylor, Stephen , Blajeski, April L., LoRusso, Patricia , Ames, Matthew M. , Reid, Joel M.

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 4 | Pages: 1471-1480

10.1158/1078-0432.ccr-0557-03 | PMID 14977851 Get It

Abstract Pyrazoloacridine (PZA) is an experimental antitumor agent presently under investigation for treatment of solid tumors on the basis of its unique mechanism of action and selectivity for human solid tumor xenograft in mice. Using capillary electrophoresis coupled with electrospray ionization mass spectrometry, we have identified three oxidative PZA metabolites, 9-desmethyl-PZA, N-demethyl-PZA, and PZA N-oxide. The cytochrome P450 (CYP) isoforms involved in PZA metabolism were characterized by studies with CYP chemical inhibitors, correlation of marker activities for selected CYPs with formation of the metabolites using a human liver panel, and PZA metabolism by cDNA-expressed CYPs. 9-Desmethyl-PZA formation was catalyzed by CYP1A2, whereas N-demethyl-PZA formation was catalyzed by CYP3A4. PZA N-oxide formation was catalyzed by flavin monooxygenase (FMO) rather than CYP, as determined by studies with chemical inhibitors of FMO and metabolism by cDNA-expressed human flavin monooxygenase. After administration of [10b-14C]PZA to mice, six urinary metabolites were detected by high-performance liquid chromatography UV and radiochromatograms including 9-desmethyl-PZA, N-demethyl-PZA, and PZA N-oxide. Trace concentrations of 9-desmethyl-PZA and PZA N-oxide were detected in mouse plasma. PZA N-oxide and N-demethyl-PZA were detected in urine from patients after PZA administration. PZA, 9-desmethyl-PZA, and PZA N-oxide inhibited growth of A375 human melanoma cells. IC50 values were 0.17, 0.11, and 7.0 μm, respectively, for the three molecules.
Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia
Kaufmann, Scott H. , Karp, Judith E. , Letendre, Louis, Kottke, Timothy, Safgren, Stephanie L. , Greer, Jackie , Gojo, Ivana , Atherton, Pamela J. , Svingen, Phyllis A., Loegering, David A., Litzow, Mark R. , Sloan, Jeff A. , Ames, Matthew M. , Adjei, Alex A. , Erlichman, Charles , Reid, Joel M. , Kaufmann, Scott H , Safgren, Stephanie L

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 18 | Pages: 6641-6649

10.1158/1078-0432.ccr-05-0817 | PMID 16166443 Get It

Abstract Purpose: To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias. Experimental Design: Patients received topotecan and carboplatin by 5-day continuous infusion at nine dose levels. Patients achieving a complete remission received up to two additional courses for consolidation. Plasma topotecan and ultrafilterable platinum were assayed on days 1 to 5. In addition, pretreatment levels of various polypeptides in leukemic cells were examined by immunoblotting to assess possible correlations with response. Results: Fifty-one patients received a total of 69 courses of therapy. Dose-limiting toxicity consisted of grade 4/5 typhlitis and grade 3/4 mucositis after one course of therapy or grade 4 neutropenia and thrombocytopenia lasting >50 days when a second course was administered on day 21. Among 45 evaluable patients, there were 7 complete remissions, 2 partial remissions, 1 incomplete complete remission, and 1 reversion to chronic-phase chronic myelogenous leukemia. Topotecan steady-state plasma concentrations increased with dose. No accumulation of topotecan or ultrafilterable platinum occurred between days 1 and 5 of therapy. Leukemic cell levels of topoisomerase I, checkpoint kinase 1, checkpoint kinase 2, and Mcl-1 correlated with proliferating cell nuclear antigen but not with response. In contrast, low Bcl-2 expression correlated with response (P = 0.014, Mann-Whitney U test). Conclusions: The maximum tolerated dose was 1.6 mg/m2/d topotecan plus 150 mg/m2/d carboplatin. The complete remission rate in a heavily pretreated population was 16% (33% at the highest three dose levels). Responses seem to correlate with low pretreatment blast cell Bcl-2 expression.
Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points
Bible, Keith C. , Lensing, Janet L., Nelson, Sacha A., Ames, Matthew M. , Isham, Crescent R., Piens, Jill, Rubin, Stacie L., Rubin, Joseph, Kaufmann, Scott H. , Atherton, Pamela J. , Sloan, Jeffrey A., Daiss, Michelle K., Adjei, Alex A. , Erlichman, Charles , Lee, Yean Kee , Reid, Joel M. , Kaufmann, Scott H

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 16 | Pages: 5935-5941

10.1158/1078-0432.ccr-04-2566 | PMID 16115936 Get It

Abstract Purpose: Flavopiridol, a cyclin-dependent kinase inhibitor, transcription inhibitor, and DNA-interacting agent, was combined with cisplatin or carboplatin to establish toxicities, evaluate pharmacokinetics, and examine its effects on patient cancers and levels of selected polypeptides in patient peripheral blood mononuclear cells (PBMC). Experimental Design: Therapy was given every 3 weeks. Stage I: cisplatin was fixed at 30 mg/m2 with escalating flavopiridol. Stage II: flavopiridol was fixed at the stage I maximum tolerated dose (MTD) with escalation of cisplatin. Stage III: flavopiridol was fixed at the stage I MTD with escalation of carboplatin. Results: Thirty-nine patients were treated with 136 cycles of chemotherapy. Neutropenia was seen in only 11% of patients. Grade 3 flavopiridol/CDDP toxicities were nausea (30%), vomiting (19%), diarrhea (15%), dehydration (15%), and neutropenia (10%). Flavopiridol combined with carboplatin resulted in unexpectedly high toxicities and one treatment-related death. Stable disease (>3 months) was seen in 34% of treated patients, but there were no objective responses. The stage II MTD was 60 mg/m2 cisplatin and 100 mg/m2/24 hours flavopiridol. As given, CDDP did not alter flavopiridol pharmacokinetics. Flavopiridol induced increased p53 and pSTAT3 levels in patient PBMCs but had no effects on cyclin D1, phosphoRNA polymerase II, or Mcl-1. Conclusions: Flavopiridol and cisplatin can be safely combined in the treatment of cancer patients. Unexpected toxicity in flavopiridol/carboplatin-treated patients attenuates enthusiasm for this alternative combination. Analysis of polypeptide levels in patient PBMCs suggests that flavopiridol may be affecting some, but not all, of its known in vitro molecular targets in vivo.
A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer
Dy, Grace K. , Bruzek, Laura M., Croghan, Gary A., Mandrekar, Sumithra J. , Erlichman, Charles , Peethambaram, Prema P. , Pitot, Henry C., Hanson, Lorelei J., Furth, Alfred, Cheng, Shinta , Martell, Robert E., Adjei, Alex A. , Reid, Joel M. , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 5 | Pages: 1877-1883

10.1158/1078-0432.ccr-04-1769 | PMID 15756013 Get It

Abstract Purpose: This phase I study was conducted to determine the toxicities, pharmacokinetics, and pharmacodynamics of BMS-214662, a farnesyl transferase inhibitor, in combination with paclitaxel and carboplatin, in patients with advanced solid tumors. Experimental Design: Patients with solid tumors received one of six escalating dose levels of BMS-214662 infused over 1 hour given following paclitaxel and carboplatin on the first day of a 21-day cycle. Toxicities were graded by the National Cancer Institute common toxicity criteria and recorded as maximum grade per patient for each treatment cycle. Inhibition of farnesyl transferase activity in peripheral blood mononuclear cells (PBMCs) was evaluated. Accumulation of unfarnesylated HDJ-2 in PBMCs of patients was evaluated as a marker of farnesyl transferase inhibition by BMS-214662. Results: Thirty patients received 141 cycles of treatment through six dose levels. Dose-limiting toxicities were neutropenia, thrombocytopenia, nausea, and vomiting. There was no pharmacokinetic interaction between BMS-214662 and paclitaxel. The maximum tolerated dose was established as BMS-214662 (160 mg/m2), paclitaxel (225 mg/m2) and carboplatin (area under the curve = 6 on day 1), every 21 days. Inhibition of HDJ-2 farnesylation in PBMCs of patients was shown. One measurable partial response was observed in a patient with taxane-resistant esophageal cancer. There was partial regression of evaluable disease in two other patients (endometrial and ovarian cancer). Stable disease (> 4 cycles) occurred in eight other patients. Conclusions: The combination of BMS-214662 with paclitaxel and carboplatin was well tolerated, with broad activity in solid tumors. There was no correlation between dose level and accumulation of unfarnesylated HDJ-2 in PBMCs nor tumor response.
Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies
LoRusso, Patricia , Adjei, Alex A. , Varterasian, Mary , Mitchell, David, Hanson, Lorelei J., DeLuca, Pamela, Bruzek, Laura M., Piens, Jill, Asbury, Peggy, Becelaere, Keri Van, Herrera, Román, Gadgeel, Shirish M. , Reid, Joel M. , Sebolt–Leopold, Judith S. , Meyer, Mark B.

Mayo Clinic

Journal of Clinical Oncology | July 12, 2005 | Volume: 23 | Issue: 23 | Pages: 5281-5293

10.1200/jco.2005.14.415 | PMID 16009947 Get It

Purpose This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK(mitogen-activated protein kinase kinase) -1 and MEK2 , in patients with advanced malignancy. Patients and Methods CI-1040 was tested in multiple daily dosing frequencies administered for 21 days repeated every 28 days leading ultimately to continuous administration, and effect of food on absorption was tested. Single dose and steady-state pharmacokinetics were assessed during cycle 1 and phosphorylated extracellular receptor kinase (pERK) levels were assessed in WBCs and also in tumor tissue from selected patients. Results Seventy-seven patients received CI-1040 at dose levels ranging from 100 mg QD to 800 mg tid. Grade 3 asthenia was dose limiting at the highest dose level tested, 800 mg tid administered with food. Ninety-eight percent of all drug-related adverse events were grade 1 or 2 in severity; most common toxicities included diarrhea, asthenia, rash, nausea, and vomiting. Plasma concentrations of CI-1040 and its active metabolite, PD 0184264, increased in a less than dose proportional manner from 100 to 800 mg QD. Administration with a high-fat meal resulted in an increase in drug exposure. The MTD and recommended phase II dose was 800 mg BID administered with food. Sixty-six patients were assessable for response. One partial response was achieved in a patient with pancreatic cancer and 19 patients (28%) achieved stable disease lasting a median of 5.5 months (range, 4 to 17 months). Inhibition of tumor pERK (median, 73%; range, 46% to 100%) was demonstrated in 10 patients. Conclusion CI-1040 was well tolerated at 800 mg BID administered with food. Both target suppression and antitumor activity were demonstrated in this phase I study.